No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALKS240517C33000
- 0.85
- 0.000.00%
15min DelayTrading Dec 26 14:20 ET
0.00High0.00Low
0.00Open0.85Pre Close0 Volume1 Open Interest33.00Strike Price0.00Turnover211.78%IV39.53%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.85Time Value100Contract SizeAmericanOptions Type0.2183Delta0.0374Gamma28.54Leverage Ratio-0.1363Theta0.0010Rho6.23Eff Leverage0.0110Vega
Intraday
- 5D
- 1D
News
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
7 Analysts Assess Alkermes: What You Need To Know
Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview of recent rat
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
Alkermes Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 45.77% HC Wainwright & Co. → $35 Reiterates Neutral → Neutral 04/19/2024 45.77% HC Wainwright &
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
Comments
Nancy S. Lurker's appointment to Alkermes' Board is viewed positively, bringing deep industry experience and commercial expertise. Her broad skills are expected to drive growth of existing products, portfolio expansion, and new product launches.
Press Release: Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsAlkermes' surplus of cash over debt and its ability to convert EBIT to free cash flow indicate a conservative balance sheet and low risk in its debt management.
Although Alkermes' share price has recently dipped, its long-term business trends are positive. Insider purchases, often seen as a good omen by investors, add further optimism.
$Alkermes(ALKS.US$ huge call options in dec, unusual. buyout for JPM healthcare conference next week?
Gainers:
• $AngioDynamics(ANGO.US$ +13.5%, $Skillsoft(SKIL.US$ +3.26%, $Sprinklr(CXM.US$ +8.96%, $Cazoo(CZOO.US$ +11.1%, $Apogee Enterprises(APOG.US$ +3.3%, $Levi Strauss & Co.(LEVI.US$ +1.7%, $Constellation Brands(STZ.US$ + 0.8%
• $Momentus(MNTS.US$ +36.9% (signed multiple launch agreements with Space Exploration Technologies Corp)
• $HP Inc(HPQ.US$ +10.1% (Berkshire Hathaway's Warren Buffett disclosed the purchase of mln sh...
• $AngioDynamics(ANGO.US$ +13.5%, $Skillsoft(SKIL.US$ +3.26%, $Sprinklr(CXM.US$ +8.96%, $Cazoo(CZOO.US$ +11.1%, $Apogee Enterprises(APOG.US$ +3.3%, $Levi Strauss & Co.(LEVI.US$ +1.7%, $Constellation Brands(STZ.US$ + 0.8%
• $Momentus(MNTS.US$ +36.9% (signed multiple launch agreements with Space Exploration Technologies Corp)
• $HP Inc(HPQ.US$ +10.1% (Berkshire Hathaway's Warren Buffett disclosed the purchase of mln sh...
15
3
Read more